Loading chat...
IN SB0439
Bill
Status
2/19/2015
Primary Sponsor
Brandt Hershman
Click for details
AI Summary
-
Medicaid will not reimburse Subutex, Suboxone, or generics for pain management unless prescribed by a physician with a federal SAMSHA waiver and valid DEA registration specifically authorizing office-based opioid treatment.
-
Prior authorization may be required for these drugs when prescribed for substance abuse treatment for more than six months or as determined by the board.
-
Reimbursement for substance abuse treatment beyond six months is limited to prescribers operating within approved opioid treatment programs under IC 12-23-18 or meeting requirements under IC 12-23-19.
-
Opioid treatment providers must periodically and randomly test patients for methadone, cocaine, opiates, amphetamines, barbiturates, THC, benzodiazepines, and other suspected drugs during treatment.
-
The division of mental health and addiction must adopt rules establishing clinical standards for patient tapering, relapse, overdose prevention, and protocols for take-home medication, patient assessment, voluntary treatment selection, and potential transition from methadone to other approved medications.
Legislative Description
Controlled substances. Limits Medicaid reimbursement for Subutex and Suboxone or an similar trade name or generic of the drug when the drug was prescribed for the treatment of pain management to only if the drug was prescribed by a physician who meets certain requirements. Allows for the office of Medicaid policy and planning to require prior authorization for these drugs when being prescribed for substance abuse treatment as determined by the board or when being prescribed for more than six months. Requires the division of mental health and addiction to adopt rules concerning: (1) opioid treatment by an opioid treatment
Last Action
First Reading: referred to Committee on Public Health
3/3/2015